These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 38949748)

  • 1. Cost and Quality of Life of Disability Progression in Multiple Sclerosis Beyond EDSS: Impact of Cognition, Fatigue, and Limb Impairment.
    Wasem J; Heer Y; Karamasioti E; Muros-Le Rouzic E; Marcelli G; Di Maio D; Braune S; Kobelt G; Dillon P
    Pharmacoecon Open; 2024 Sep; 8(5):665-678. PubMed ID: 38949748
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The socioeconomic impact of disability progression in multiple sclerosis: A retrospective cohort study of the German NeuroTransData (NTD) registry.
    Dillon P; Heer Y; Karamasioti E; Muros-Le Rouzic E; Marcelli G; Di Maio D; Braune S; Kobelt G; Wasem J
    Mult Scler J Exp Transl Clin; 2023; 9(3):20552173231187810. PubMed ID: 37529629
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Exploratory clinical efficacy and patient-reported outcomes from NOVA: A randomized controlled study of intravenous natalizumab 6-week dosing versus continued 4-week dosing for relapsing-remitting multiple sclerosis.
    Ryerson LZ; Foley JF; Defer G; Cohen JA; Arnold DL; Butzkueven H; Cutter G; Giovannoni G; Killestein J; Wiendl H; Sinks S; Kuhelj R; Bodhinathan K; Lasky T
    Mult Scler Relat Disord; 2023 Apr; 72():104561. PubMed ID: 36931078
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Multiple Sclerosis Functional Composite and Symbol Digit Modalities Test as outcome measures in pediatric multiple sclerosis.
    Brenton JN; Koshiya H; Woolbright E; Goldman MD
    Mult Scler J Exp Transl Clin; 2019; 5(2):2055217319846141. PubMed ID: 31065380
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The EDSS-Plus, an improved endpoint for disability progression in secondary progressive multiple sclerosis.
    Cadavid D; Cohen JA; Freedman MS; Goldman MD; Hartung HP; Havrdova E; Jeffery D; Kapoor R; Miller A; Sellebjerg F; Kinch D; Lee S; Shang S; Mikol D
    Mult Scler; 2017 Jan; 23(1):94-105. PubMed ID: 27003945
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Erratum.
    Mult Scler; 2016 Oct; 22(12):NP9-NP11. PubMed ID: 26041800
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effect of multi-function swing suspension training on upper and lower extremities function and quality of life in multiple sclerosis women with different disability status.
    Far SS; Amiri B; Sahebozamani M; Ebrahimi HA; Zemková E
    Mult Scler Relat Disord; 2023 Dec; 80():105113. PubMed ID: 37924713
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Influence of Education, Cognition, and Physical Disability on Quality of Life of Romanian Patients with Multiple Sclerosis-A Cohort Study.
    Ciubotaru A; Ignat EB; Alexa D; Grosu C; Păvăleanu I; Manole A; Maștaleru A; Leon MM; Matei DV; Azoicăi D
    Medicina (Kaunas); 2024 Feb; 60(3):. PubMed ID: 38541112
    [No Abstract]   [Full Text] [Related]  

  • 9. Short-term impact of fampridine on motor and cognitive functions, mood and quality of life among multiple sclerosis patients.
    Pavsic K; Pelicon K; Ledinek AH; Sega S
    Clin Neurol Neurosurg; 2015 Dec; 139():35-40. PubMed ID: 26363365
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative utility of disability progression measures in PPMS: Analysis of the PROMiSe data set.
    Koch MW; Cutter GR; Giovannoni G; Uitdehaag BMJ; Wolinsky JS; Davis MD; Steinerman JR; Knappertz V
    Neurol Neuroimmunol Neuroinflamm; 2017 Jul; 4(4):e358. PubMed ID: 28680915
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Japanese translation and validation of the 12-item Multiple Sclerosis Walking Scale version 2.
    Miyazaki Y; Niino M; Takahashi E; Sato C; Naganuma R; Amino I; Akimoto S; Minami N; Kikuchi S
    Mult Scler Relat Disord; 2024 Sep; 89():105768. PubMed ID: 39003823
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Binocular low-contrast letter acuity and the symbol digit modalities test improve the ability of the Multiple Sclerosis Functional Composite to predict disease in pediatric multiple sclerosis.
    Waldman AT; Chahin S; Lavery AM; Liu G; Banwell BL; Liu GT; Balcer LJ
    Mult Scler Relat Disord; 2016 Nov; 10():73-78. PubMed ID: 27919503
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical impact of 20% worsening on Timed 25-foot Walk and 9-hole Peg Test in multiple sclerosis.
    Kragt JJ; van der Linden FA; Nielsen JM; Uitdehaag BM; Polman CH
    Mult Scler; 2006 Oct; 12(5):594-8. PubMed ID: 17086905
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of multiple sclerosis disability outcome measures using pooled clinical trial data.
    Goldman MD; LaRocca NG; Rudick RA; Hudson LD; Chin PS; Francis GS; Jacobs A; Kapoor R; Matthews PM; Mowry EM; Balcer LJ; Panzara M; Phillips G; Uitdehaag BMJ; Cohen JA;
    Neurology; 2019 Nov; 93(21):e1921-e1931. PubMed ID: 31641014
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical outcome measures in SPMS trials: An analysis of the IMPACT and ASCEND original trial data sets.
    Koch MW; Mostert J; Uitdehaag B; Cutter G
    Mult Scler; 2020 Oct; 26(12):1540-1549. PubMed ID: 31517591
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predictors of Health Utility in Relapsing-Remitting and Secondary-Progressive Multiple Sclerosis: Implications for Future Economic Models of Disease-Modifying Therapies.
    Hernandez L; O'Donnell M; Postma M;
    Pharmacoeconomics; 2021 Feb; 39(2):243-256. PubMed ID: 32989685
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of machine learning-based classification of clinical impairment and prediction of clinical worsening in multiple sclerosis.
    Noteboom S; Seiler M; Chien C; Rane RP; Barkhof F; Strijbis EMM; Paul F; Schoonheim MM; Ritter K
    J Neurol; 2024 Aug; 271(8):5577-5589. PubMed ID: 38909341
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impairment of daily occupations in multiple sclerosis: analysis of neuroimaging, general and social cognition, and reserve.
    Gomes LR; Damasceno BP; de Campos BM; Damasceno A
    Mult Scler Relat Disord; 2024 Jan; 81():105140. PubMed ID: 37988860
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fall risk is related to cognitive functioning in ambulatory multiple sclerosis patients.
    Bilgin YOU; Koskderelioglu A; Gedizlioglu M
    Neurol Sci; 2023 Sep; 44(9):3233-3242. PubMed ID: 36997775
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Patient reported outcomes in a secondary progressive MS cohort related to cognition, MRI and physical outcomes.
    Theodorsdottir A; Nielsen HH; Ravnborg MH; Illes Z
    Mult Scler Relat Disord; 2023 Mar; 71():104550. PubMed ID: 36842312
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.